Search

Your search keyword '"Puglianini, Omar Castaneda"' showing total 17 results
Start Over Author "Puglianini, Omar Castaneda"
17 results on '"Puglianini, Omar Castaneda"'

1. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Author

Zanwar, Saurabh, Sidana, Surbhi, Shune, Leyla, Puglianini, Omar Castaneda, Pasvolsky, Oren, Gonzalez, Rebecca, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Davis, James A., Herr, Megan, Hashmi, Hamza, Forsberg, Peter, Sborov, Douglas, Anderson Jr, Larry D., McGuirk, Joseph P., Wagner, Charlotte, Lieberman-Cribbin, Alex, Rossi, Adriana, Freeman, Ciara L., Locke, Frederick L., Richard, Shambavi, Khouri, Jack, Lin, Yi, Patel, Krina K., Kumar, Shaji K., and Hansen, Doris K.

Published
2024
Full Text
View/download PDF

2. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Jr., Larry D., and Lin, Yi

Published
2024
Full Text
View/download PDF

3. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Peres, Lauren, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, Mehmet, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, McGuirk, Joseph, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Davis, James, additional, Kaur, Gurbakash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher, additional, Gaballa, Mahmoud, additional, Janakiram, Murali, additional, nadeem, omar, additional, Midha, Shonali, additional, Wagner, Charlotte, additional, Locke, Frederick, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

4. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

5. P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, M Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Ferreri, Christopher, additional, Wagner, Charlotte, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

6. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

7. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Mohammed, Turab, primary, Shahzad, Moazzam, additional, Peres, Lauren, additional, Khadka, Sushmita, additional, Colinleitzinger, Christelle, additional, Babu, Abida, additional, Doyle, William, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, De Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Smith, Eric, additional, Corallo, Salvatore, additional, Khimani4, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hien, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

8. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience

Author

Puglianini, Omar Castaneda, primary, Hansen, Doris K, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon Jamaal, additional, Brayer, Jason, additional, Freeman, Ciara, additional, Shain, Kenneth, additional, Liu, Hien, additional, Ochoa, Leonel, additional, Locke, Frederick L., additional, Baz, Rachid, additional, Alsina, Melissa, additional, and Nishihori, Taiga, additional

Published
2023
Full Text
View/download PDF

9. Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience

Author

Mohty, Razan, primary, Nishihori, Taiga, additional, Faramand, Rawan G, additional, Hansen, Doris K, additional, Nieder, Dr. Michael L., additional, Lazaryan, Aleksandr, additional, Besaw, Laura, additional, Smith, Meredith Tate, additional, Rowe, Jolene, additional, Mishra, Asmita, additional, Pidala, Joseph A., additional, Bejanyan, Nelli, additional, Alsina, Melissa, additional, Khimani, Farhad, additional, Puglianini, Omar Castaneda, additional, Perez, Lia Elena, additional, Elmariah, Hany, additional, Jain, Michael D, additional, Ochoa-Bayona, Jose Leonel, additional, Locke, Frederick L., additional, and Liu, Hien, additional

Published
2023
Full Text
View/download PDF

11. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

Author

Puglianini, Omar Castaneda, Peker, Deniz, Zhang, Linsheng, and Papadantonakis, Nikolaos

Subjects
*MYELOFIBROSIS
Abstract

Although several decades have passed since the description of myeloproliferative neoplasms (MPN), many aspects of their pathophysiology have not been elucidated. In this review, we discuss the mutational landscape of patients with essential thrombocythemia (ET), prognostic scores and salient pathology, and clinical points. We discuss also the diagnostic challenges of differentiating ET from prefibrotic MF. We then focus on post-essential thrombocythemia myelofibrosis (post-ET MF), a rare subset of MPN that is usually studied in conjunction with post-polycythemia vera MF. The transition of ET to post-ET MF is not well studied on a molecular level, and we present available data. Patients with secondary MF could benefit from allogenic hematopoietic stem cell transplantation, and we present available data focusing on post-ET MF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA

Author

Lee, Dae Hyun, primary, Chandrasekhar, Sanjay Amrith, additional, Jain, Michael, additional, Hansen, Doris, additional, Freeman, Ciara, additional, Alsina, Melissa, additional, Baz, Rachid, additional, Puglianini, Omar Castaneda, additional, Liu, Hien, additional, Blue, Brandon, additional, Davila, Marco L., additional, Faramand, Rawan, additional, Kumar, Abhishek, additional, Shah, Bijal, additional, Lazaryan, Aleksandr, additional, Khimani, Farhad, additional, Nishihori, Taiga, additional, Bachmeier, Christina, additional, Locke, Frederick, additional, Oliveira, Guilherme Henrique, additional, and Alomar, Mohammed, additional

Published
2022
Full Text
View/download PDF

14. 490 - Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience

Author

Mohty, Razan, Nishihori, Taiga, Faramand, Rawan G, Hansen, Doris K, Nieder, Dr. Michael L., Lazaryan, Aleksandr, Besaw, Laura, Smith, Meredith Tate, Rowe, Jolene, Mishra, Asmita, Pidala, Joseph A., Bejanyan, Nelli, Alsina, Melissa, Khimani, Farhad, Puglianini, Omar Castaneda, Perez, Lia Elena, Elmariah, Hany, Jain, Michael D, Ochoa-Bayona, Jose Leonel, Locke, Frederick L., and Liu, Hien

Published
2023
Full Text
View/download PDF

17. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.

Author

Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, and Alsina M

Subjects
Humans, Male, Female, Middle Aged, Aged, Biological Products therapeutic use, Biological Products administration & dosage, Adult, B-Cell Maturation Antigen immunology, Antigens, CD19 immunology, Antigens, CD19 therapeutic use, Recurrence, Treatment Outcome, Aged, 80 and over, Drug Resistance, Neoplasm, United States epidemiology, Recombinant Fusion Proteins administration & dosage, Recombinant Fusion Proteins therapeutic use, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen therapeutic use, Risk Factors, Multiple Myeloma therapy, Multiple Myeloma immunology, Multiple Myeloma mortality, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive adverse effects, Disease Progression
Abstract

While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma ≤3 months after CAR T-cell infusion) in patients treated with standard of care ide-cel at 11 US academic centers. Among 211 patients that received ide-cel, 43 patients had a progressive event ≤3 months of infusion. Patients with a history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, use of bridging therapy, Hispanic ethnicity, plasma cell leukemia and t(4;14) were more likely to progress ≤3 months of infusion (P<0.05). Of these risk factors for early progression identified in univariate analyses, history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, plasma cell leukemia, and t(4;14) were associated with worse progression-free survival (PFS) in multivariable analysis. Presence of three or more of these factors had a significant negative impact on PFS (P<0.001; median PFS for ≥3 factors, 3.2 months vs. 0 factors, 14.1 months). This study helps identify patients at high risk of early progression after CAR T-cell therapy who may benefit from specific interventions pre and post CAR T-cell therpy to improve outcomes.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results